Advanced Solid Malignancies Completed Phase 1 Trials for Selumetinib (DB11689)

Also known as: Advanced Solid Malignancy

IndicationStatusPhase
DBCOND0034803 (Advanced Solid Malignancies)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01605916Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerTreatment